EPA:ALPHA - Euronext Paris - Matif - FR001400N1P4 - Common Stock - Currency: EUR
EPA:ALPHA (8/26/2024, 7:00:00 PM)
0.0002
+0 (+100%)
The current stock price of ALPHA.PA is 0.0002 EUR. In the past month the price decreased by -33.33%. In the past year, price decreased by -100%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 18.25 | 290.75B | ||
AMG.DE | AMGEN INC | 13.94 | 136.71B | ||
1AMGN.MI | AMGEN INC | 14.47 | 135.46B | ||
1GILD.MI | GILEAD SCIENCES INC | 14.1 | 119.24B | ||
GIS.DE | GILEAD SCIENCES INC | 14.07 | 118.98B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 101.05B | ||
ARGX.BR | ARGENX SE | 107.45 | 30.84B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 23.81B | ||
IDP.DE | BIOGEN INC | 8.38 | 17.08B | ||
1MRNA.MI | MODERNA INC | N/A | 9.44B | ||
0QF.DE | MODERNA INC | N/A | 9.31B | ||
BIO.DE | BIOTEST AG | N/A | 1.69B |
Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Suresnes, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.
Pharnext
14 rue de la Republique
Suresnes ILE-DE-FRANCE FR
Employees: 0
Phone: 33141092230
The current stock price of ALPHA.PA is 0.0002 EUR. The price increased by 100% in the last trading session.
The exchange symbol of Pharnext is ALPHA and it is listed on the Euronext Paris - Matif exchange.
ALPHA.PA stock is listed on the Euronext Paris - Matif exchange.
9 analysts have analysed ALPHA.PA and the average price target is 12750 EUR. This implies a price increase of 6374999900% is expected in the next year compared to the current price of 0.0002. Check the Pharnext stock analysts ratings, price target forecast and up-and down grades for more detailed information.
Pharnext (ALPHA.PA) has a market capitalization of 1.19K EUR. This makes ALPHA.PA a Nano Cap stock.
Pharnext (ALPHA.PA) currently has 0 employees.
The Revenue of Pharnext (ALPHA.PA) is expected to decline by -22.9% in the next year. Check the estimates tab for more information on the ALPHA.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALPHA.PA does not pay a dividend.
Pharnext (ALPHA.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-26278826.88).
ChartMill assigns a fundamental rating of 1 / 10 to ALPHA.PA. ALPHA.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months ALPHA.PA reported a non-GAAP Earnings per Share(EPS) of -26278826.88. The EPS increased by 99.99% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -627.44% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 87% to ALPHA.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 99.81% and a revenue growth -22.9% for ALPHA.PA